Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients with high-grade gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). EGFR/IL13Rα2 pool-CAR T cells are a type of CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony diagnosis glejaka IV stopnia lub astrocytoma IV stopnia IDH-mutant
- •Choroba nawróciła po leczeniu standardowym, co najmniej 12 tygodni po radioterapii
- •Wyniki testów immunologicznych wykazują ekspresję IL13Rα2 i zmianę genu EGFR
- •Liczba białych krwinek powyżej 2000/dl, płytki krwi co najmniej 75 000/mm3
- •Hemoglobina powyżej 9 g/dL
- •Saturacja tlenu co najmniej 95% oddychając zwykłym powietrzem
- •Kobiety w wieku rozrodczym - ujemny test ciążowy
✗ Disqualifies
- •Otrzymywanie aktualnie leczenia bevacizumabem (ze względu na ryzyko powikłań)
- •Niezupełne wyleczenie skutków ubocznych poprzednich terapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
City of Hope Medical Center
Duarte, United States
Trial contact
Behnam Badie
Behnam Badie
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.